acetaminophen has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, GA; Caldwell, KA; Fox, SA; Locke, CJ | 1 |
| Ammar, RM; El-Bahy, AAZ; El-Naga, RN; Labib, AY; Michel, HE; Tadros, MG | 1 |
2 other study(ies) available for acetaminophen and alpha-synuclein
| Article | Year |
|---|---|
Acetaminophen attenuates dopamine neuron degeneration in animal models of Parkinson's disease.
Topics: Acetaminophen; Adrenergic Agents; alpha-Synuclein; Analgesics, Non-Narcotic; Animals; Animals, Genetically Modified; Caenorhabditis elegans; Cell Count; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression Regulation; Green Fluorescent Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinson Disease; Tyrosine 3-Monooxygenase | 2008 |
Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation.
Topics: Acetaminophen; alpha-Synuclein; Animals; Apoptosis; Corpus Striatum; Dopamine; Endocannabinoids; Male; Mesencephalon; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rotenone | 2021 |